Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 33: 44-47, 1987;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kin, N. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kin, N. M.

Clinical Chemistry, Vol 33, 44-47, Copyright © 1987 by American Association for Clinical Chemistry

Comparison of the urinary glycoconjugates excreted by patients with type I and type II fucosidosis

NM Kin

Glycoconjugates were isolated, by repeated chromatography on Biogel P- 4, from urine of two patients with different phenotypes of fucosidosis, type I (acute) and type II (chronic). Studies of the isolated compounds with thin-layer chromatography, chromatography on Biogel P-4, gas- liquid chromatography, and 1H- and 13C-nuclear magnetic resonance spectroscopy showed differences in the excretion patterns of fucosyl glycoconjugates in the urine of these patients. The amount of the diglycosylasparagine, fuc alpha 1-6glcNAc-Asn, excreted was significantly lower for the type I than for the type II patient. On the other hand, the reducing hexasaccharide gal beta 1-4(fuc alpha 1- 3)glcNAc beta 1-2man alpha 1-3/6man beta 1-4glcNAc was present in much greater quantities in urine from the type I patient. The differences in the excretion patterns of these glycoconjugates may be attributed to different substrate specificities for the residual alpha-L-fucosidases in the two forms of the disease. I propose that such differences may be exploited for the early laboratory diagnosis of the type II form of the disease, particularly by thin-layer chromatography.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American Association for Clinical Chemistry.